Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:EJHaem
Hlavní autoři: Gunther, Jillian R., Pinnix, Chelsea C., Glober, Gordon R., Christopherson, Kaitlin M., Fang, Penny, Lee, Hun Ju, Ahmed, Sairah, Steiner, Raphael E., Nair, Ranjit, Strati, Paolo, Neelapu, Sattva S., Nastoupil, Loretta J., Dabaja, Bouthaina S.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Short Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7455016/
https://ncbi.nlm.nih.gov/pubmed/32864660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jha2.1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky